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Abstract Epimerase deficiency galactosemia is an autoso-
mal recessive disorder that results from partial impairment
of UDP-galactose 40-epimerase (GALE), the third enzyme
in the Leloir pathway of galactose metabolism. Clinical
severity of epimerase deficiency ranges from potentially
lethal to apparently benign, likely reflecting the extent of
GALE enzyme impairment, among other factors. We report
here a case study of monozygotic twins identified by
newborn screening with elevated total galactose and normal
galactose-1P uridylyltransferase (GALT). Follow-up testing
revealed partial impairment of GALE in hemolysates but
near-normal activity in lymphoblasts; molecular testing
identified a missense substitution, R220W, apparently in
the homozygous state. The twins were treated with dietary
galactose restriction for the first 18 months of life. During
this time, independent testing revealed concurrent diagno-
ses of Williams Syndrome in both twins, and cytomegalo-
virus (CMV) infection in one. Expression studies of
R220W-hGALE in a null-background strain of Saccharo-
myces cerevisiae demonstrated a very limited impairment of
Vmax for UDP-galactose (UDP-Gal) and Km for UDP-N-
acetylgalactosamine (UDP-GalNAc), but a galactose chal-
lenge in vivo failed to uncover any evidence of impaired
Leloir function. Similarly, both twins demonstrated normal
hemolysate galactose-1-phosphate (Gal-1P) levels follow-
ing normalization of their diets at 18 months of age. While
these studies cannot rule out a negative consequence from
some cryptic GALE impairment in a specific tissue or
developmental stage, they suggest that the substitution,
R220W, is mild to neutral, so that any GALE impairment in
these twins is likely to be peripheral and therefore unlikely




UDP-Gal Uridine diphosphate galactose
UDP-GalNAc Uridine diphosphate-N-acetyl-D-galactosamine
UDP-Glc Uridine diphosphate gluctose
UDP-GlcNAc Uridine diphosphate-N-acetyl-D-glucosamine
Introduction
The galactosemias are a family of genetic disorders that
result from impaired ability to metabolize galactose; these
autosomal recessive conditions are caused by mutations
that compromise either the expression or function of
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galactokinase (GALK, EC 2.7.1.6), galactose-1-phosphate
uridylyltransferase (GALT, EC 2.7.7.12), or UDP-galactose
40-epimerase (GALE, EC 5.1.3.2), the three enzymes of the
Leloir pathway (Fridovich-Keil and Walter 2008). The
symptoms and severity of these conditions vary in
response to which enzyme is impaired and the extent of
the impairment; other genetic and environmental factors
remain poorly understood.
Epimerase deficiency (MIM# 230350), also called Type
III galactosemia, results from partial impairment of GALE
and is perhaps the least well understood of the galactosemias.
Fewer than 10 patients with severe GALE impairment,
resulting in a clinical presentation similar to that of classic
transferase deficiency galactosemia, have been reported
(Holton et al. 1981; Sarkar et al. 2010; Walter et al. 1999);
these patients are said to have generalized epimerase
deficiency (Fridovich-Keil et al. 2011). Similar to patients
with classic galactosemia, patients with generalized
epimerase deficiency respond well to dietary restriction of
galactose, which prevents the potentially lethal acute
symptoms, although long-term complications may persist
(Henderson and Holton 1983; Sarkar et al. 2010; Walter
et al. 1999).
Most patients with epimerase deficiency are asymptomatic
in infancy and are identified through newborn screening in
jurisdictions that measure both GALT activity and total
galactose in every sample; the blood spots from these infants
show elevated total galactose despite normal GALT
(Fridovich-Keil et al. 2011). Follow-up enzymatic testing of
hemolysates from patients with epimerase deficiency
galactosemia demonstrates partial to profound loss of GALE
activity. Enzymatic testing of fibroblasts or transformed
lymphoblasts reveals a broad range of impairment from
essentially normal GALE activity down to 15–20% of
normal (Gitzelmann and Steimann 1973; Gitzelmann et al.
1976; Mitchell et al. 1975; Openo et al. 2006). Individuals
with normal or near-normal GALE activity in cell types
other than red blood cells are said to have peripheral
epimerase deficiency, and are believed to remain asymptom-
atic (Fridovich-Keil et al. 2011; Gitzelmann et al. 1976).
Individuals who show partial impairment of GALE activity
in cell types other than red blood cells are said to have
intermediate epimerase deficiency (Openo et al. 2006); the
long-term outcomes for these patients remain unknown as
nearly all are lost to follow-up at an early age (Alano et al.
1998; Fridovich-Keil et al. 2011; Quimby et al. 1997;
Wohlers et al. 1999).
More than 20 different, ostensibly causal genetic variants
have been identified in the GALE loci of patients with
biochemically confirmed epimerase deficiency; a subset of
these alleles and the GALE proteins they encode have been
studied in vitro and/or in vivo, revealing a range of degrees
and mechanisms of impairment (Alano et al. 1998; Bang
et al. 2009; Chhay et al. 2008b; Henderson et al. 2001;
Maceratesi et al. 1996, 1998; Openo et al. 2006; Park et al.
2005; Quimby et al. 1997; Thoden et al. 2001b; Timson
2005; Wohlers and Fridovich-Keil 2000; Wohlers et al.
1999). Some variant GALE proteins are catalytically
impaired, while others demonstrate compromised stability,
at least under defined laboratory conditions. While the
relationship between GALE activity and galactose-sensitivity
has been defined in yeast and Drosophila models
(Sanders et al. 2010; Wasilenko and Fridovich-Keil 2006),
the relationship between GALE activity level and outcome
severity in patients remains a point of speculation.
We report a case study on the discordant clinical,
biochemical, and genetic phenotypes of monozygotic twins
with partial GALE deficiency identified by newborn screening
on the basis of normal GALT and elevated total galactose
levels. Both twins were apparently homozygous for a novel
variant of GALE (R220W) and had multiple concurrent
abnormalities including severe vitamin D–deficiency rickets,
moderate bilateral sensorineural hearing loss, and genomic
deletions consistent with Williams syndrome. Our report
illustrates the complexity of comorbidities that can exist in a
single patient and serves as a reminder that not every genetic
variant is causal of the clinical abnormalities present.
Materials and Methods
Study subjects: The twins, designated here as FKE065 and
FKE066, were ascertained by referral from their metabolic
nurse practitioner; informed consent was obtained in
accordance with Emory University Institutional Review
Board Protocol 618–99. Control samples were ascertained
as anonymous blood samples from nongalactosemic
individuals, also in accordance with IRB protocol 618–99.
The hemolysate biochemical data listed here were gener-
ated in clinical labs, as noted.
Mutational analysis of the hGALE locus: Mutational
analysis of the hGALE loci in both twins was performed in a
CLIA-approved clinical laboratory by direct sequencing of
PCR-amplified fragments of genomic DNA representing all
coding exons and their immediate flanking intronic sequen-
ces. Each amplicon was sequenced in both the forward and
reverse directions and nucleotide changes were interpreted
using the Human Genome Mutation Database (HGMD) and
dbSNP database. The functional significance of the R220W
substitution in hGALE was estimated using three software
systems: SIFT (http://sift.jcvi.org/, Ng and Henikoff 2003),
PANTHER (Thomas et al. 2003), and Polyphen 2 (http://
genetics.bwh.harvard.edu/pph2/, Adzhubei et al. 2010).
Lymphoblast studies: EBV-transformed lymphoblasts were
prepared from patient and control blood samples as described
previously (Neitzel 1986). Transformed lymphoblasts were
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maintained in RPMI-1640 medium (Hyclone) containing
glucose (2 g/L) and L-glutamine (0.3 g/L) and supplemented
with penicillin (100 U/mL), streptomycin (100 mg/mL),
25 mmol/L Hepes, and 10% (v/v) fetal bovine serum (FBS)
(Gibco/Invitrogen, Carlsbad, CA, USA). All cells were
maintained at 37 C in a humidified 5% CO2 incubator
(NuAire, Plymouth, MN, USA).
GALT and GALE enzyme analyses of lymphoblast cell
lysates: Lymphoblast cell cultures were harvested and
lysates prepared and analyzed for GALT and GALE
activities as described previously (Openo et al. 2006).
Enzyme activity was defined in units of pmol product
produced/min/mg soluble protein.
Plasmids and yeast strains: The R220W substitution was
re-created by site-directed mutagenesis of a wild-type human
GALE coding sequence within the context of a centromeric
yeast expression plasmid (MM33) that has been previously
described (Chhay et al. 2008b). Mutagenesis was carried out
using the Quick-change system (Stratagene, Inc.) according
to the manufacturer’s instructions using the following
primer sequences (lower case letters indicate the mutation
to be created): hGALE.R220W.f1 50 GTGGCGATCGGGC-
GAtGGGAGGCCCTGAATGTC 30 and hGALE.R220W.r1
50 GACATTCAGGGCCTCCCaTCGCCCGATCGCCAC 30.
The entire hGALE open reading frame of the resulting
plasmid (pMM33.hGALE.R220W) was confirmed by
dideoxy sequencing. The corresponding positive (wild-type
hGALE) and negative (plasmid backbone only) plasmid
controls have been reported previously (Chhay et al. 2008b;
Wohlers et al. 1999).
All yeast strains used in this study were derived by
transformation of JFy3835, a GAL10-null haploid strain of
Saccharomyces cerevisiae that lacks endogenous GALE
and has been described reviously (Chhay et al. 2008b). For
in vitro biochemical assays, yeast cultures were maintained
in standard synthetic medium containing 2% dextrose (SD)
at 28 C. For growth curves, yeast were cultured in standard
synthetic medium containing 2% glycerol and 2% ethanol
(SGE) at 30 C, with or without the addition of galactose,
as indicated.
Enzyme assays of yeast soluble lysates: Yeast proteins
were extracted from cells harvested from SD cultures at
OD600 between 0.8 and 1.2 by vigorous agitation with glass
beads, as previously described (Chhay et al. 2008b).
Soluble lysates were passed over P-6 Bio-Spin columns
(Bio-Rad) to remove small metabolites prior to further
analysis. The protein concentration in each sample was
determined using the Bio-Rad protein assay reagent as
recommended by the manufacturer using a standard curve
of BSA. GALE and GALT enzyme activities were
measured as described previously (Chhay et al. 2008b).
Kinetic studies of each protein were performed in triplicate
over a range of five different concentrations of substrate
(UDP-Gal or UDP-GalNAc) with NAD+ held constant, at
0.5 mM, and also in triplicate over a range of five different
concentrations of NAD+ with substrate held constant (UDP-
Gal at 0.8 mM or UDP-GalNAc at 0.66 mM). Data were
analyzed by SigmaPlot 11.0 software using the ligand-
binding plot of the Michaelis–Menten equation (1/V ¼ Km/
(Vmax [S]) + 1/Vmax).
Yeast growth assays in the presence of galactose: Yeast
growth assays were performed as described previously
(Chhay et al. 2008a).
Statistical analyses: Statistical analyses were performed
using the JMP 8.0.1 software package. Data were analyzed
using linear regression, one-way ANOVA, or t-test. The
results were considered statistically significant if P < 0.05.
Case History
Infants FKE065 and FKE066 were delivered from a
diamniotic dichorionic twin pregnancy in a 26-year-old,
gravida 4 mother. The prenatal course was complicated by
maternal iron deficiency anemia and growth restriction for
fetus FKE065. Amniotic fluid testing for each fetus
revealed a normal 46,XX female karyotype. Breech
presentation led to cesarean section delivery of small-for-
gestational-age twins with Apgar scores 6 at 37-5/
7 weeks gestation. Polymerase chain reaction (PCR)-based
DNA zygosity testing of the twins and their mother
indicated a 98.2% probability of monozygosity. Parents
are of indigenous Ecuadorian ancestry with no known
consanguinity.
Neonatal complications were significant for failed
hearing screenings for both twins, and heart murmur and
mild jaundice for FKE066 that resolved without photother-
apy. On the seventh day of life when abnormal newborn
screening results for galactosemia were reported (Table 1),
exclusively soy formula feedings were initiated. On the
11th day of life, during the initial metabolic consultation
(Table 1), the twins had normal physical examinations and
normal alanine aminotransferase levels (Table 2). Diag-
nostic testing revealed impairment of GALE enzymatic
activity in hemolysates in the affected range (Table 1). At
9 weeks of age during metabolic follow-up, the twins were
found to have new onset jaundice, cholestasis, conjugated
hyperbilirubinemia, elevated liver transaminases without
coagulopathy, gastroesophageal reflux, and failure to
thrive, prompting prolonged hospitalizations (Table 2).
Throughout their hospitalizations, failure to thrive
persisted despite high-caloric soy formula intake and
fat-soluble vitamin supplementation. Neither twin had
hepatomegaly. Biliary atresia was discounted by radionu-
clide imaging. Renal findings in both twins included
generalized amino aciduria with echogenic kidneys and
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interstitial nephritis. They also had severe bone deminerali-
zation and subacute fractures leading to diagnoses of severe
vitamin D–deficient rickets (Table 2). The rickets diagnoses
were attributed to probable severe maternal vitamin D
deficiency, although maternal testing was unable to be
completed. Osteogenesis imperfecta gene sequencing
(COL1A1 and COL1A2) was later performed for FKE066
with negative results.
Table 1 Biochemical, enzymatic, and molecular testing results
FKE065 FKE066 Reference Ranges
GALT enzyme
activitya
12.7 13.4 Control: 3.2 units/g Hb
Total galactose levela 38.3 30.3 Control: 18.0 mg%
Galactose-1-
phosphateb
<0.1c,, 0.2c, 0.1c, 0.8d, 0.1 d, <0.1d 0.2c, 0.1c, 0.1c, 0.2d, 0.4d, 0.2d, 0.5d Control: 0.0–1.0 mg%
Galactitol, urine 22.6c,e, 19.0c,e, 32.7c,e 29.9c,e, 26.0c,e, 38.6c,e Control: 0–94.7 mmol/mol Cr
GALE enzyme
activityb
5.8,10.1 9.0, 7.9 Control: 17.1–40.1 mmol/h/g Hb
Carrier: 12–20 mmol/h/g Hb




28.7 26.9 Control: 22.2–45.8 mmol/h/g Hb
Galactosemia
isozymes
N/N N/N Control: N/N
GALK enzyme
activityb







Control: no mutations detected
a Blood spot newborn screen collected at 36 h of age
b Red blood cells
c Galactose-restricted diet (Gal-1P measured at <1, 8, and 13 months for FKE065 and at <1, 6, and 8 months for FKE066; galactitols collected
twice at 2+ months and again at 3 months for each twin)
d Galactose-unrestricted diet (Gal-1P measured at 15, 21, and 34 months for FKE065 and 13, 15, 21, and 34 months for FKE066)
e Symptomatic cholestatic jaundice (9–16 weeks of age)
Table 2 Hepatic and endocrine laboratory results
FKE065 FKE066 Normal reference range
Alanine aminotransferase 4a,c, 44–215b,c, 47d 8a,c, 29–235b,c, 15d, 26e 0–50 u/L
Aspartate aminotransferase 79–435b,c, 66d 62–399b,c, 76d, 33e 0–50 u/L
Alkaline phosphatase 683–1264b,c,189d 822–2285b,c, 190d,164e 110–420 u/L
Bilirubin, conjugated 0.0–4.5b,c, 0.0d 0.0–3.0b,c, 0.0d 0–0.3 mg/dL
Bilirubin, total 1.3–7.6b,c,<0.1d 0.7–5.9b,c, 0.6d, 0.4e 0.2–1.3 mg/dL
Bilirubin, delta 0.8–2.5b,c, 0.0 d 0.3–1.8b,c, 0.5d 0.0–0.4 mg/dL
Gamma-glutamyltransferase 520b,c Not measured 0–130 u/L
Serum calcium 7.2–10.0b,c, 10.0d 7.7–9.6b,c, 10.3d 9–11 mg/dL
Ionized calcium 3.2–5.7b,c, 5.1d 3.6–5.8b,c, 5.2d 5.1–6.3 mg/dL
Serum phosphorus 1.1–4.9b,c, 5.0d 1.6–3.9b,c, 5.9d 3.9–6.5 mg/dL
Parathyroid hormone, intact 151–641b,c 175–929b,c 12–72 pg/mL
25-hydroxyvitamin D, total <10–< 36b,c, <38d <10–32b,c,<34d 30 mg/L
a Asymptomatic, day 11 of age
b Acutely symptomatic 9–16 weeks of age
c Galactose-restricted diet (<1–4 months of age)
d Obtained at age 34 months (after 16 consecutive months on galactose-unrestricted diet without calcium or vitamin D supplementation)
e Obtained at age 56 months (after 38 consecutive months on a galactose-unrestricted diet)
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FKE066 had a cardiac murmur and mild supravalvar
pulmonary stenosis. FKE065 also developed a cardiac
murmur and was found to have supravalvar and branch
pulmonary artery stenosis. Extensive infectious disease
testing was negative for FKE066. FKE065 had high levels
of cytomegalovirus (CMV) by DNA testing using PCR on
multiple occasions, leading to liver biopsy at 12 weeks of age
that suggested CMV hepatitis, and was treated with intrave-
nous ganciclovir. Both infants had normal transcranial
ultrasounds and normal ophthalmology examinations.
At hospital discharge, both infants showed healing
rickets, correction of vitamin D deficiency after aggressive
oral and IV therapy, resolution of cholestatic jaundice with
ursodiol treatment and improvement of liver enzymes
(Table 2).
In mid-infancy, both twins had high-resolution chromo-
some banding (46,XX), and array comparative genomic
hybridization studies performed that demonstrated copy
number losses consistent with deletions within band
7q11.23; FISH with a probe spanning the LIMK and
D7S613 loci confirmed the deletions and diagnoses of
Williams syndrome. Subtle facial dysmorphism characteristic
of Williams syndrome first became apparent for the infants at
8–11 months of age. By 16–21 months of age, both children
had bitemporal narrowing, periorbital fullness, and full lips.
FKE066 also had a coarse voice. By 5–8 months of age, the
twins had hypotonia, brisk deep tendon reflexes, and
language and gross motor delays. Neuropsychological
evaluation at 10 months of age using the Bayley Scales of
Infant and Toddler Development (Third Edition) documented
pervasive developmental delays with cognitive, language,
and motor age equivalencies in the 2–5 month range for
both infants. Global developmental delays persisted; both
twins sat unsupported at 13 months and walked indepen-
dently at 28–29 months of age. At age 3 years, they
remained largely nonverbal, hypotonic, and globally
developmentally delayed.
GALE gene sequencing for each twin revealed apparent
homozygosity for a previously unreported variant predicted by
homology studies to be likely causative of GALE deficiency
(Table 1). Their mother was later determined to be heterozy-
gous for this sequence variant. Paternal genetic testing was
unable to be performed. Galactose restriction was maintained
throughout infancy as the GALE deficiency evaluation
remained in progress, with galactose challenges undertaken
at 13–15 months of age (Table 1). By 18 months of age, both
children were on normal diets, unrestricted in galactose. Post-
galactose challenge evaluations revealed normal eye exami-
nations and no elevation of hemolysate Gal-1P for either twin
(Table 1), and a normal liver ultrasound for FKE065.
At the time of this report, FKE065 has required 10
additional hospitalizations with subsequent bacteremia,
gastrostomy tube placement (later removed), systemic
hypertension requiring antihypertensive therapy (resolved),
acute renal insufficiency (resolved), and marked thoracic
scoliosis. FKE066 has required two additional hospital-
izations for respiratory infections. Both children have
moderate bilateral sensorineural hearing loss. They have
been discharged from further metabolic follow-up.
Results
hGALE and hGALT Activity in Patient
Lymphoblast Cells
To characterize the ostensible GALE impairment in these
twins, we prepared EBV-transformed lymphoblasts from
each and tested the resulting cell lysates for GALT and
GALE activities (Fridovich-Keil et al. 2011; Openo et al.
2006). Three control lines (FKT901, FKT934, and GM)
and one from a patient previously diagnosed with interme-
diate epimerase deficiency galactosemia (FKE084) were
analyzed in parallel.
Standard GALE assays of lysates from FKE065 and
FKE066 demonstrated no significant impairment relative to
the three unaffected controls (Fig. 1a, P ¼ 0.4671) while
the affected lysate, FKE084, demonstrated only about 21%
of control activity (P < 0.0001). Of note, GALE activities
detected in lymphoblasts from the twins (FKE065 and
FKE066) differed by close to a factor of 2; this range was
also observed in lymphoblasts from different unaffected
controls (Fig. 1a; Openo et al. 2006). As expected, the
GALT activity levels in all six cell lines were indistinguish-
able (P ¼ 0.1986, Fig. 1b).
Characterization of Human GALE-R220W Expressed
in Yeast
To assess the functional significance of the R220W
substitution in a more controlled setting, we recreated the
variation by site-directed mutagenesis and expressed the
resultant allele from a low-copy (CEN) plasmid in a null-
background strain of S. cerevisiae, JFy3835 (Chhay et al.
2008b). Parallel cultures of yeast expressing wild-type
human GALE (WT) or no GALE (bb only) served as
positive and negative controls, respectively (Wohlers et al.
1999; Quimby et al. 1997).
Under normal assay conditions (Chhay et al. 2008b)
using either UDP-Gal or UDP-GalNAc as substrate,
hGALE-R220W demonstrated >50% wild-type activity
(Fig. 2a and 2b). However, the apparent Vmax values for
the wild-type and hGALE-R220W proteins differed by
about two-fold when the substrate was UDP-Gal (Table 3),
and the apparent Km values differed by about a factor of
2 when the substrate was UDP-GalNAc (Table 4). These
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Vmax and Km differences might explain why the apparent
activity of the hGALE-R220W-substituted protein was
reduced by close to twofold relative to the wild-type
protein when measured using the standard assay (Fig. 2).
We also tested for possible impact of the R220W substitu-
tion on cofactor dependence of the enzyme activity (Frey
1996; Thoden et al. 1996, 2001a) by monitoring reactions
performed under initial conditions of fixed substrate concen-
tration and varying amounts of exogenous NAD+. Although
some patient mutations have been shown to disrupt hGALE
interactions with NAD+ (Quimby et al. 1997), we saw no
evidence of such an impact by R220W (Fig. 3).
Fig. 1 GALE and GALT enzyme activity levels in control and patient
lymphoblast cells. EBV-transformed lymphoblast cells cultured in
complete RPMI-1640 medium with 10% FBS were collected by
centrifugation and soluble lysates were prepared. FKT901, FKT934,
and GM were derived from non-galactosemic controls (white bars).
FKE065 and FKE066 represent the twins reported here (gray bars).
FKE084 represents a patient with previously diagnosed intermediate
epimerase deficiency (black bar). (a) GALE and (b) GALT enzyme
activities were measured as described in Materials and Methods. Activity
is expressed as mean  SEM (n  4) pmol/min/mg soluble protein
Fig. 2 Enzyme activity of R220W-hGALE expressed in null-back-
ground yeast. Colonies were inoculated from GAL10-null yeast
transformed with plasmids encoding either wild-type hGALE (WT),
no hGALE (backbone (bb) only), or R220W-hGALE (R220W).
Cultures were expanded and harvested, and lysates prepared as
described in Materials and Methods. GALE enzyme activity was
monitored using either (a) UDP-Gal or (b) UDP-GalNAc as substrate.
Activity is expressed as mean  SEM (n  4) pmol/min/mg soluble
protein
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Galactose Sensitivity of Yeast Expressing hGALE-R220W
Finally, we measured the galactose-sensitivity of yeast
expressing hGALE-R220W as their only GALE enzyme.
Previously, we have demonstrated that the growth rate of
yeast with compromised GALE activity is diminished in
medium containing glycerol-ethanol as the carbon source
when trace levels of galactose are spiked into the medium,
and this effect is dose dependent (Ross et al. 2004;
Wasilenko and Fridovich-Keil 2006). Here we tested the
growth rates of yeast expressing wild-type hGALE (WT),
no hGALE (bb only), or hGALE-R220W (R220W), each
cultured in synthetic glycerol-ethanol medium without
galactose vs. with 0.002% or 0.02% galactose added at
t = 0 (Fig. 4). In medium lacking galactose, all three of the
strains grew well (Fig. 4a), while in medium spiked with
galactose, yeast expressing either wild-type hGALE or
hGALE-R220W grew well, but yeast missing GALE did
not (Fig. 4b, c). These data confirm that hGALE-R220W
encodes a GALE enzyme that is predominantly, if not fully,
functional in living yeast cells.
Discussion
The purpose of this study was threefold. First, we wanted to
illustrate the complex challenges of elucidating the clinical
phenotype of epimerase deficiency in patients with concur-
rent comorbidities. In this case, outcome was confounded by
the presence of additional genetic (Williams syndrome) and
environmental (CMV and vitamin D deficiency) issues; had
there not been a pair of monozygotic twins, both of whom
shared the same GALE genotype, but who demonstrated
discordant outcomes for some symptoms, it might have been
tempting to attribute more of the clinical complications to
compromised GALE function.
Second, we wanted to address the question: How does one
distinguish a functionally neutral or near-neutral variant from a
functionally significant GALE mutation, especially when the
genetic background of the patient may be distinct from that of
publicly available control populations? That the variant found
in this family had not been reported in control populations
(e.g., HapMap) of predominantly European, Asian, or African
Fig. 3 Effect of NADþ on GALE activity detected in lysates of yeast
expressing wild-type vs. R220W-hGALE. GALE assays were per-
formed as described in Materials and Methods using soluble lysates of
yeast expressing either wild-type hGALE or R220W-hGALE. (a) The
initial concentration of substrate UDP-Gal was held constant at
0.8 mM; (b) the initial concentration of substrate UDP-GalNAc was
held constant at 0.66 mM; NAD+ concentration was varied as
indicated. Activity is expressed as mean  SEM (n  4) pmol/min/
mg soluble protein





(mean  SEM mM)
Apparent UDP-Gal Vmax
(mean  SEM pmol/
min/mg protein)
WT 0.314  0.014 456.69  6.35
R220W 0.274  0.023 212.58  5.49*
Assays to determine the Km and Vmax of UDP-Gal were performed
at the concentration of 0.5 mM NAD+ . Kinetic constants were
determined by fitting the data to a ligand-binding plot by SigmaPlot
11.0. All values are averages  SEM (n ¼ 3) of three independent
analyses
*Indicates P  0.05






(mean  SEM mM)
Apparent UDP-GalNAc
Vmax (mean  SEM pmol/
min/mg protein)
WT 0.165  0.038 114.39  7.24
R220W 0.339  0.045* 111.62  5.47
Assays to determining the Km and Vmax of UDP-GalNAc were
performed at the concentration of 0.5 mM NAD+ . Kinetic constants
were determined by fitting the data to a ligand-binding plot by
SigmaPlot 11.0. All values are averages  SEM (n ¼ 3) of three
independent analyses
*Indicates P  0.05
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ancestry may not be particularly informative given that the
family traces their roots to Ecuador. The situation described
here was further complicated by the observation that the
twins are apparently homozygous for this novel variant.
Testing of the father was never performed and it remains
possible that he is a carrier of a GALE allele, such as a
deletion, that escapes detection by our assay and therefore
results in apparent homozygosity of the other allele. If the
twins are truly homozygous for the R220W variant allele, it
might be common in the relevant ancestral population.
Alternatively, there might be some unrecognized shared
ancestry between the parents, leading to concern that the
twins might be homozygous at other loci, as well, and these
cryptic homozygosities might underlie at least some of the
apparent clinical abnormalities. Of note, consanguinity was a
known confounding factor in both affected families of the
first patients reported with generalized epimerase deficiency
galactosemia (Henderson and Holton 1983; Holton et al.
1981; Sardharwalla et al. 1988; Walter et al. 1999) who
demonstrated a variety of developmental or other disabilities.
A patient reported more recently (Sarkar et al. 2010), who
also presented with acutely symptomatic epimerase defi-
ciency in infancy, responded well to dietary restriction of
galactose and apparently has not exhibited developmental
delays; it is unknown whether there is consanguinity in that
family.
Finally, we wanted to address the balanced relationship
between in silico predictions of functional significance of
amino acid substitutions, predictions from in vitro studies
of recombinant proteins, and indicators of function in vivo
in a yeast model system. As discussed below, in silico,
in vitro, and in vivo studies can give disparate results,
leading to the need for a judgment call that balances the
weight of the accumulated clinical and laboratory data.
Arguments pointing toward clinically significant
epimerase deficiency: The initial newborn screening result
of the twins showed elevated total galactose at about twice
the normal cut-off (Table 2). Repeat follow-up hemolysate
GALE enzyme assays showed reduced activity within
the affected range (Table 1) and apparent homozygosity for
a novel variant of GALE (R220W) that in silico prediction
tools classified as likely to be of functional significance.
Polyphen-2 predicted this amino acid replacement as “proba-
bly damaging” with a score 1.00. The arginine at position 220
in the GALE protein is conserved among numerous
mammalian species. In addition, arginine is conserved at
position 220 in the amphibian Xenopus as well as in various
species of fish indicating that this amino acid is conserved
through many different vertebrates. Indeed, only chicken had
a different amino acid, glutamine, at this position.
Arguments pointing away from functionally significant
epimerase deficiency galactosemia: The neonatal presenta-
tion of the twins was unremarkable despite the fact that
both infants were on a milk diet, that the lymphoblast
GALE activity assay showed essentially normal values, and
that the yeast expression studies demonstrated only very
marginally lowered GALE activity in vitro and no apparent
GALE defect in vivo. It is important to note that acute
jaundice and other complications did not present until
months after the diet had been switched to exclusively soy
formula (Case History). The marginal elevation of total
galactose in the newborn screens, coupled with the
intermediate and variable hemolysate GALE results
reported for both twins from follow-up studies, leaves open
the question of the functional significance of these data.
Indeed, that the twins were delivered at less than 38 weeks
gestation and small for gestational age suggests that
“immature liver” might have contributed to the newborn
Fig. 4 Yeast expressing R220W-hGALE demonstrate no apparent
growth-sensitivity to galactose. Cultures of null-background yeast
expressing either wild-type hGALE (WT), no hGALE (bb only), or
R220W-hGALE (R220W) were inoculated into the wells of 96-well
plates at a density of 5 105 cells/mL at t ¼ 0 in SGE-Ura synthetic
medium supplemented with the indicated amount of galactose.
Growth of each culture was monitored as described in Materials and
Methods. Values plotted represent means  SEM (n ¼ 9). (a) All
cultures grew well in the absence of galactose. (b) Addition of 0.002%
galactose halted the growth of yeast lacking hGALE but not yeast
expressing WT or R220W-hGALE. (c) Addition of 0.02% galactose
halted the growth of yeast lacking hGALE but not yeast expressing
WT or R220W-hGALE
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screening results (Fridovich-Keil et al. 2011; Ono et al.
1999). Finally, when taken off the galactose-restricted diet
at 18 months, Gal-1P did not elevate in either twin,
suggesting that the Leloir pathway in these infants was
functioning, at least at that point.
Neutral variant or significant mutation? Novel missense
variants at any genomic locus in a symptomatic patient are
typically assessed for functional significance initially by
two approaches: (1) querying prevalence of the variant in
relevant affected and control populations and (2) in silico
prediction programs that utilize multiple sequence align-
ments and structural information.
The twins reported here are apparently homozygous for
an allele of GALE that has not been described previously;
this suggests only that the allele may be uncommon in
European and other studied populations. We have no
information on the frequency of this allele among the
indigenous peoples of Ecuador.
Due to the complex clinical picture of the twins
(Williams syndrome and sensorineural hearing loss), addi-
tional steps were taken to test the functional significance of
the identified missense variation; these included biochemi-
cal studies of transformed patient lymphoblasts, and in vitro
and in vivo measures of GALE function in a null-
background yeast strain engineered to express the relevant
patient allele (R220W-hGALE). All of these measures
demonstrated near-normal GALE activity, suggesting the
R220W substitution does not significantly disrupt hGALE
function, at least in non-peripheral cells. These results are
consistent with a diagnosis of peripheral epimerase defi-
ciency in FKE065 and FKE066. Some small differences
(e.g., Km or Vmax) were detected in some assays between
R220W-hGALE and the unaffected control; however, these
differences were generally no more than a factor of 2,
which is unlikely to impact clinical outcome in a recessive
condition. Of course, we cannot rule out that the R220W
substitution might have some significant but cryptic impact
not tested for here, for example, restricted to a specific
tissue, or time in development.
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